Kevin Conroy/LinkedIn
Jul 11, 2025, 16:16
Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer
Kevin Conroy, Chairman & CEO of Exact Sciences, shared a post on LinkedIn:
“Our MRD test, Oncodetect, is now covered by Medicare for serial use in patients with stage II, III, and resectable stage IV colorectal cancer. This decision means even more patients can benefit from earlier, more precise answers about their care. Thankful for the Exact Sciences team whose work made this possible, and proud of what it means for patients.”
Read Full Article on Exact Sciences.
Read More About Immunotherapy for CRC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32